These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23677743)

  • 1. Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults.
    Perrino PJ; Colucci SV; Apseloff G; Harris SC
    Clin Drug Investig; 2013 Jun; 33(6):441-9. PubMed ID: 23677743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.
    Harris SC; Perrino PJ; Smith I; Shram MJ; Colucci SV; Bartlett C; Sellers EM
    J Clin Pharmacol; 2014 Apr; 54(4):468-77. PubMed ID: 24243216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Particle size affects pharmacokinetics of milled oxycodone hydrochloride tablet products following nasal insufflation in nondependent, recreational opioid users.
    Raofi S; Kinjo M; Sun D; Li Z; Boyce H; Natarajan K; Frost M; Zhao L; Luke M; Lionberger R; Kelsh D; Kim MJ
    Clin Transl Sci; 2021 Sep; 14(5):1977-1987. PubMed ID: 33982418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.
    Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB
    Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
    Friedmann N; Marsman MR; de Kater AW; Burns LH; Webster LR
    J Opioid Manag; 2018; 14(6):437-443. PubMed ID: 30629280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation.
    Webster LR; Iverson M; Pantaleon C; Smith MD; Kinzler ER; Aigner S
    Pain Med; 2019 Apr; 20(4):747-757. PubMed ID: 29608768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.
    Schoedel KA; Rolleri RL; Faulknor JY; Pixton GC; Chen N; Bass A; Sommerville KW; Sellers E
    J Opioid Manag; 2012; 8(5):315-27. PubMed ID: 23247908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
    Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
    Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
    J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
    Sellers EM; Perrino PJ; Colucci SV; Harris SC
    J Psychopharmacol; 2013 Sep; 27(9):808-16. PubMed ID: 23784739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions.
    Devarakonda K; Morton T; Margulis R; Giuliani M; Barrett T
    Drug Des Devel Ther; 2014; 8():1125-34. PubMed ID: 25170252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone.
    Webster LR; Kopecky EA; Smith MD; Fleming AB
    Pain Med; 2016 Jun; 17(6):1112-30. PubMed ID: 26814256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
.
    Scheidel B; Maritz MA; Gschwind YJ; Steigerwald K; Guth V; Kovacs P; Rey H
    Int J Clin Pharmacol Ther; 2017 Nov; 55(11):881-890. PubMed ID: 28933336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.
    Setnik B; Bass A; Bramson C; Levy-Cooperman N; Malhotra B; Matschke K; Geoffroy P; Sommerville KW; Wolfram G
    Pain Med; 2017 Jun; 18(6):1077-1088. PubMed ID: 27550954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparative pharmacokinetics of physical manipulation by crushing of Xtampza
    Brennan MJ; Kopecky EA; Marseilles A; O'Connor M; Fleming AB
    Pain Manag; 2017 Nov; 7(6):461-472. PubMed ID: 29171358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets.
    Franke RM; Morton T; Devarakonda K
    Drug Des Devel Ther; 2015; 9():4587-97. PubMed ID: 26316698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.
    Kopecky EA; Fleming AB; Noonan PK; Varanasi RK; Grima M; Saim S; Mayock SP
    J Opioid Manag; 2014; 10(4):233-46. PubMed ID: 25162603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone.
    Kirkpatrick DL; Schmidt WK; Morales R; Cremin J; Seroogy J; Husfeld C; Jenkins T
    J Opioid Manag; 2017; 13(1):39-49. PubMed ID: 28345745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.